Over the last 12 hours, the most CBD/cannabis-relevant thread is legal and regulatory pressure on the industry—especially around federal rescheduling and its downstream effects. Multiple items focus on the U.S. shift of marijuana from Schedule I to Schedule III, including commentary that rescheduling could reduce major federal tax and compliance burdens (notably Section 280E) and potentially improve access to banking and lending for marijuana-related businesses. In parallel, new litigation coverage highlights consumer-facing risk claims: companies including Cresco, Curaleaf, Green Thumb Industries, and Verano are named in proposed class actions alleging they failed to warn consumers about health risks. Separately, a hemp-focused lawsuit alleges a delivery service stole and sold a $2.5M shipment, underscoring ongoing supply-chain and enforcement vulnerabilities for hemp operators.
Another major development in the last 12 hours is the continued fallout from an FBI raid tied to Virginia state Sen. L. Louise Lucas and a neighboring dispensary. Coverage describes Lucas framing the raid as political intimidation, while other reporting says the corruption investigation began during the Biden administration. While this is not a “CBD policy” update per se, it is directly connected to a cannabis business and signals heightened federal scrutiny that could affect operators’ compliance posture and risk management.
There is also evidence of industry-level momentum and product/clinical innovation in the same window. Incannex Healthcare was recognized for drug development solutions, with the award tied to cannabinoid-based medicine development and a broader pipeline that includes cannabinoid combination products and psychedelic-inspired regimens. Meanwhile, MAPS added two directors to its board, expanding leadership and financial stewardship for the psychedelic field—adjacent to CBD’s broader cannabinoid ecosystem, though not a CBD-specific regulatory change.
Outside the last 12 hours, the broader background reinforces that rescheduling is a central narrative driver and that state-level rules remain uneven. Earlier coverage includes discussion of how rescheduling could reshape industry economics and research access, plus ongoing state-level disputes and enforcement actions (including hemp THC restrictions and court challenges in Texas). However, the most recent 12-hour evidence is comparatively rich on litigation, federal rescheduling implications, and the Virginia raid—while other CBD-specific developments are sparse in the immediate window.